Core Viewpoint - MicroPort Robotics-B (02252) reported a significant increase in revenue and a reduction in net losses for the six months ending June 30, 2025, indicating strong growth and market acceptance of its products [1] Financial Performance - The company achieved revenue of 176 million, representing a year-on-year increase of 77% [1] - Adjusted net loss was 97.1 million, a decrease of 55.5% compared to the previous year [1] - Loss attributable to equity shareholders was 113 million, down 59.1% year-on-year [1] - Earnings per share loss was 0.11 [1] Revenue Growth Drivers - Revenue growth was primarily driven by the rapid commercialization of multiple products, particularly in overseas markets, which saw a substantial year-on-year increase of 189% [1] - The core product, the TiMAY endoscopic surgical robot, continued to show strong growth, with overseas markets being the main engine for revenue increase [1] - The Honghu orthopedic surgical robot leveraged MicroPort Medical Group's established sales network to achieve rapid coverage and penetration in key regions, while also expanding into emerging areas, creating a "dual-engine" growth model [1] - The R-ONE vascular interventional surgical robot, after its market launch, gained recognition and saw steady demand growth [1]